Daniel Busby
Stock Analyst at RBC Capital
(2.74)
# 2,046
Out of 4,981 analysts
6
Total ratings
66.67%
Success rate
22.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $160 → $40 | $4.83 | +728.16% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $23.87 | +84.33% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $5.57 | -10.23% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $218.34 | -38.17% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $160 → $40
Current: $4.83
Upside: +728.16%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $23.87
Upside: +84.33%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $5.57
Upside: -10.23%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $218.34
Upside: -38.17%